Business Wire

NORTHERN-DATA-AG

21.7.2020 07:34:11 CEST | Business Wire | Press release

Share
Northern Data AG: Successful Development Partnership With Gigabyte Technology

Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87 ), one of the world's largest providers of high-performance-computing (HPC) solutions, has developed proprietary HPC services in cooperation with the leading Taiwanese computer hardware manufacturer Gigabyte Technology (Taiwan Stock Exchange: 2376, ISIN: TW0002376001 ).

Northern Data's partnership with Gigabyte covers the production, supply and combination of components, where Northern Data tests specific processors (GPUs, CPUs, etc.) and selects them for the respective applications and Gigabyte combines these processors with its specialised server architecture. In doing so, Gigabyte adjusts the GPU clusters developed by Northern Data to meet all of Northern Data's technical requirements. A GPU cluster is a computer network in which each node (processing unit) is equipped with several Graphic Processing Units (GPU). The high-density GPU clusters used in these processes are specially designed for high-performance-computing (HPC) applications.

The server architecture created on this basis is the foundation for so-called distributed computing. Distributed computing involves running software across multiple computer systems working in parallel, in order to increase their efficiency, reliability and performance. With these new, tailor-made high-density GPU clusters, Northern Data can meet the highly specific requirements of their customers, providing them with the required computing power for their respective HPC applications as easily and efficiently as possible. This service will then be used in Northern Data's data centers for individually developed customer solutions.

GPU-based, parallel processing of data enables highly complex, computationally intensive HPC applications to be executed efficiently, reliably and quickly, particularly in the domains of artificial intelligence and rendering.

This combination of Gigabyte's expertise in manufacturing HPC hardware and Northern Data's experience in managing and orchestrating large-scale facilities (with proprietary AI software and its own thermal management system) opens up new opportunities for Northern Data customers to scale their operations even further than before. Northern Data distinguishes itself from other providers by the composition and combination of hardware and software, the way it is made available and, above all, by the favourable pricing for customers.

"The demand for HPC is booming; the rendering and AI sectors are enormous growth markets. We are pleased to have Gigabyte Technologies, one of the leading suppliers in the young HPC sector, on board as our development partner, and we are now excited to announce this business partnership," explains Aroosh Thillainathan, CEO of Northern Data AG, and continues: "We have already worked together on various GPU-based HPC projects, as we believe that Gigabyte's servers are among the best hardware for HPC in the world. Hence, we are very pleased to deepen our partnership with a manufacturer with this level of expertise and to have them accompany our R&D process. Gigabyte is the right strategic partner to help us make the concept of distributed computing a reality for many HPC applications".

Northern Data CFO Mathis Schultz adds: "So far, our customers are predominantly in the bitcoin mining sector, which was the first mass-scale HPC application. But the demand from other sectors is growing rapidly, accelerated in part by the Covid-19 crisis. The partnership with Gigabyte Technologies allows us to build out our market-leading position with bitcoin mining clients, into new sectors."

And Thomas Yen, European head of Gigabyte Technologies explains: "We are pleased to now officially announce our partnership with Northern Data. We see great potential in our jointly-designed GPU clusters. We are excited to work closely with Northern Data as a strategic partner and high-potential customer in the field of HPC."

About Northern Data:

Northern Data AG builds and offers global infrastructure solutions in the field of high-performance computing (HPC), offering solutions in the fields of machine learning and artificial intelligence, big data analytics, blockchain applications, game streaming and more. Operating internationally the company evolved from the merger of German Northern Bitcoin AG and American Whinstone US, Inc. and is now a recognized leader in the provision of HPC solutions worldwide. The company offers HPC solutions, both stationary in large state-of-the-art data centers as well as in high-tech mobile data centers, which can be deployed in any location worldwide. In doing so, it combines self-developed software and hardware with novel concepts to ensure a sustainable and reliable energy supply. In Texas, Northern Data is running the USA's largest HPC data center and, at the same time, the world's largest dedicated HPC facility. Further information can be found at www.northerndata.de .

About Gigabyte Technology Co., Ltd.

Gigabyte Technology Co., Ltd. is a Taiwan-based company principally engaged in the production, processing and sales of information technology (IT) products. The company provides computer motherboards, three dimensional (3D) display graphic cards, laptops, tablets, personal computers (PCs), servers, smart phones, broadband network devices and wireless communication products, computer peripherals and network storage products. It distributes its products mainly within Taiwan, as well as to the rest of Asia, Europe and the Americas.

Disclaimer:

This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice.

Language: English
Company: Northern Data AG
Thurn-und-Taxis-Platz 6
60313 Frankfurt/Main
Germany
Phone: +49 69 34 87 52 25
E-mail: info@northerndata.de
Internet: www.northerndata.de
ISIN: DE000A0SMU87
WKN: A0SMU8
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate Exchange
EQS News ID:

1097883

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye